KRAS and non-small cell lung carcinoma: Newly developed next-generation TKIs, including osimertinib for EGFR mutations, lorlatinib and brigatinib for ALK re-arrangement, sotorasib and adagrasib for KRAS G12C mutations, and entrectinib for ROS1 rearrangement, are currently US-FDA approved next-line treatment for NSCLC patients with respective resistance following primary therapy.